mhurhangee/ep-ind-claims huggingface dataset:
Mold for molding a hollow body from a preform of said a hollow body, said mold defining a molding cavity having the shape of the a hollow body to be molded and comprising a first part and a second part, said parts (18, 20) being movable relative to each other between an opened configuration of the mold, wherein the preform can be loaded inside the molding cavity, and a closed configuration of the mold, wherein the molding cavity is formed and wherein the first part and the second part define an outer contour, the mold further comprising a locking element arranged to maintain the mold in its closed configuration in a locked position of the mold, the locking element comprising at least a sleeve portion comprising an inner opening opened at its upper portion, characterized in that said outer portion has a lower portion and an upper portion joined together by a shoulder extending substantially radially, said sleeve portion being arranged around the lower portion of the outer contour in the closed configuration such that said sleeve portion surrounds said lower portion and prevents the mold from moving towards its open configuration in the locked position of the mold, the lower portion of the outer contour being engaged in the inner opening and the shoulder coming into abutment on the upper end of the inner opening such that the upper portion of the outer contour extends above the sleeve portion in said locked position of the mold.
A bispecific antibody fusion protein that binds human OX40 and human serum albumin, and antagonizes the binding of OX40 to OX40L, the bispecific antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (V H 1), a CHI domain and a second heavy chain variable domain (V H 2), a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (V L 1), a CL domain and a second light chain variable domain (V L 2), wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site, wherein the antigen bound by the first antigen binding site is human OX40 and the antigen bound by the second antigen binding site is human serum albumin, wherein the first variable domain of the heavy chain (V H 1) comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the first variable domain of the light chain (V L 1) comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, wherein the second heavy chain variable domain (V H 2) has the sequence given in SEQ ID NO:11 and the second light chain variable domain (V L 2) has the sequence given in SEQ ID NO: 12 and the second heavy chain variable domain (V H 2) and second light chain variable domain (V L 2) are linked by a disulphide bond. a heavy chain comprising, in sequence from the N-terminal, a first heavy chain variable domain (V H 1), a CHI domain and a second heavy chain variable domain (V H 2), a light chain comprising, in sequence from the N-terminal, a first light chain variable domain (V L 1), a CL domain and a second light chain variable domain (V L 2), wherein said heavy and light chains are aligned such that VH1 and VL1 form a first antigen binding site and VH2 and VL2 form a second antigen binding site, wherein the antigen bound by the first antigen binding site is human OX40 and the antigen bound by the second antigen binding site is human serum albumin, wherein the first variable domain of the heavy chain (V H 1) comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the first variable domain of the light chain (V L 1) comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, wherein the second heavy chain variable domain (V H 2) has the sequence given in SEQ ID NO:11 and the second light chain variable domain (V L 2) has the sequence given in SEQ ID NO: 12 and the second heavy chain variable domain (V H 2) and second light chain variable domain (V L 2) are linked by a disulphide bond.
A method for cultivating cells utilizing wave motion, comprising the steps of: - providing a container (2; 2A; 2B), retaining means (7; 7A; 7B; 57) for retaining the container, and a driving mechanism (4, 8; 4, 8, 8B, 20; 54, 58, 64, 68, 78) for swivelling the container with respect to a substantially horizontal pivot axis (5; 5B; 55); - introducing a gas containing oxygen, a liquid medium and a cell culture into the container; - moving the container such that the container swivels with respect to said substantially horizontal pivot axis (5; 5B; 55) to thereby induce a wave motion to the liquid medium in the container, which wave motion contributes to the necessary oxygen transfer and mixing required for cell growth, characterized in that said pivot axis (5; 5B; 55) is defined as a central axis of a hinge joint located at an attachment of the retaining means (7; 7A; 7B; 57) to a rotating beam (8; 8B; 58) of the driving mechanism 4, 8; 4, 8, 8B, 20; 54, 58, 64, 68, 78), and in that during said swivelling of the container said pivot axis (5; 5B; 55) follows a cyclical closed-loop path (6; 6B; 56). - providing a container (2; 2A; 2B), retaining means (7; 7A; 7B; 57) for retaining the container, and a driving mechanism (4, 8; 4, 8, 8B, 20; 54, 58, 64, 68, 78) for swivelling the container with respect to a substantially horizontal pivot axis (5; 5B; 55); - introducing a gas containing oxygen, a liquid medium and a cell culture into the container; - moving the container such that the container swivels with respect to said substantially horizontal pivot axis (5; 5B; 55) to thereby induce a wave motion to the liquid medium in the container, which wave motion contributes to the necessary oxygen transfer and mixing required for cell growth, characterized in that said pivot axis (5; 5B; 55) is defined as a central axis of a hinge joint located at an attachment of the retaining means (7; 7A; 7B; 57) to a rotating beam (8; 8B; 58) of the driving mechanism 4, 8; 4, 8, 8B, 20; 54, 58, 64, 68, 78), and in that during said swivelling of the container said pivot axis (5; 5B; 55) follows a cyclical closed-loop path (6; 6B; 56).
A sustained release tablet comprising: - 14.00 to 24.00 mg of molsidomine, - 45.00 to 80.00 mg of calcium monohydrogen phosphate dihydrate, - 35.00 to 60.00 mg of a lipophilic matrix agent, - 15.00 to 45.00 mg of microcrystalline cellulose, - 0.10 to 10.00 mg of anhydrous colloidal silica, and - 0.50 to 5.00 mg of magnesium stearate, wherein said tablet is obtained by a direct compression method. - 14.00 to 24.00 mg of molsidomine, - 45.00 to 80.00 mg of calcium monohydrogen phosphate dihydrate, - 35.00 to 60.00 mg of a lipophilic matrix agent, - 15.00 to 45.00 mg of microcrystalline cellulose, - 0.10 to 10.00 mg of anhydrous colloidal silica, and - 0.50 to 5.00 mg of magnesium stearate,
A system, comprising: a memory subsystem; a first subsystem with a first kernel address space; a second subsystem with a second kernel address space; and an input/output memory management unit, IOMMU,; wherein the system is configured to: allocate, by the first subsystem, a block of memory at a first physical address in a physical address space corresponding to the memory subsystem; characterised in that the system is further configured to: create, by the first subsystem, a mapping of a first logical address in the first kernel address space to the first physical address, wherein the first logical address in the first kernel address space is a first offset away from the first physical address; select, by the IOMMU, a device address that is a second offset away from the first logical address in the second kernel address space; create an IOMMU mapping of the selected device address in the device address space to the first physical address; and enable, with the IOMMU mapping, a common shared region in both the first kernel address space and the second kernel address space for use by both the first subsystem and the second subsystem. a memory subsystem; a first subsystem with a first kernel address space; a second subsystem with a second kernel address space; and an input/output memory management unit, IOMMU,; wherein the system is configured to: allocate, by the first subsystem, a block of memory at a first physical address in a physical address space corresponding to the memory subsystem; characterised in that the system is further configured to: create, by the first subsystem, a mapping of a first logical address in the first kernel address space to the first physical address, wherein the first logical address in the first kernel address space is a first offset away from the first physical address; select, by the IOMMU, a device address that is a second offset away from the first logical address in the second kernel address space; create an IOMMU mapping of the selected device address in the device address space to the first physical address; and enable, with the IOMMU mapping, a common shared region in both the first kernel address space and the second kernel address space for use by both the first subsystem and the second subsystem. create, by the first subsystem, a mapping of a first logical address in the first kernel address space to the first physical address, wherein the first logical address in the first kernel address space is a first offset away from the first physical address; select, by the IOMMU, a device address that is a second offset away from the first logical address in the second kernel address space; create an IOMMU mapping of the selected device address in the device address space to the first physical address; and enable, with the IOMMU mapping, a common shared region in both the first kernel address space and the second kernel address space for use by both the first subsystem and the second subsystem.
A method of making a metal panel assembly, the method comprising: - providing a first metal panel having a first body portion and a first flange along a margin of the first body portion adjacent a first end of the first body portion; - providing a second metal panel having a second body portion and a second flange along a margin of the second body portion adjacent a second end of the second body portion; - providing an elongate adhesive sheet having a first portion near a first end of the width of the elongate adhesive sheet and a second portion near a second end opposite to the first end of the elongate adhesive sheet, the elongate adhesive sheet comprising a thermosettable composition, the elongate adhesive sheet having on at least one major surface a plurality of microstructures; - applying the elongate adhesive sheet to said first or second metal panel; - folding the first flange of the first panel over said second flange of said second panel; whereby a metal joint is obtained wherein the elongate adhesive sheet is folded such that the first portion of the elongate adhesive sheet is between the second flange of said second panel and said first body portion of said first panel and the second portion of the elongate adhesive sheet is between said first flange of said first panel and said second flange of said second panel; - heating the metal joint so as to cause thermosetting of the thermosettable composition of the elongate adhesive sheet, thereby adhering said first and second metal panel and sealing the metal joint. - providing a first metal panel having a first body portion and a first flange along a margin of the first body portion adjacent a first end of the first body portion; - providing a second metal panel having a second body portion and a second flange along a margin of the second body portion adjacent a second end of the second body portion; - providing an elongate adhesive sheet having a first portion near a first end of the width of the elongate adhesive sheet and a second portion near a second end opposite to the first end of the elongate adhesive sheet, the elongate adhesive sheet comprising a thermosettable composition, the elongate adhesive sheet having on at least one major surface a plurality of microstructures; - applying the elongate adhesive sheet to said first or second metal panel; - folding the first flange of the first panel over said second flange of said second panel; whereby a metal joint is obtained wherein the elongate adhesive sheet is folded such that the first portion of the elongate adhesive sheet is between the second flange of said second panel and said first body portion of said first panel and the second portion of the elongate adhesive sheet is between said first flange of said first panel and said second flange of said second panel; - heating the metal joint so as to cause thermosetting of the thermosettable composition of the elongate adhesive sheet, thereby adhering said first and second metal panel and sealing the metal joint.
A self-propelled vehicle comprising: - a light emitting device for emitting light pulses; and - an imaging device for capturing images of the surroundings of the self-propelled vehicle, the imaging device comprising light sensors and a shutter; wherein - the light emitting device is coordinated with the shutter of the imaging device, such that an image of the surroundings of the self-propelled vehicle is captured by the imaging device during at least part of the duration of a light pulse; - the light emitting device is configured to emit light pulses wherein each light pulse has a duration of less than 5000 μs; and - the self-propelled vehicle is an aerial drone; characterized in that the imaging device is configured to convert light to electrical signals without using any electrical amplifier to provide gain to image signals generated by the light sensors of the imaging device, and in that the light pulses are light pulses of high power in order to reduce image noise in the images captured by the imaging device. - a light emitting device for emitting light pulses; and - an imaging device for capturing images of the surroundings of the self-propelled vehicle, the imaging device comprising light sensors and a shutter; wherein - the light emitting device is coordinated with the shutter of the imaging device, such that an image of the surroundings of the self-propelled vehicle is captured by the imaging device during at least part of the duration of a light pulse; - the light emitting device is configured to emit light pulses wherein each light pulse has a duration of less than 5000 μs; and - the self-propelled vehicle is an aerial drone; characterized in that the imaging device is configured to convert light to electrical signals without using any electrical amplifier to provide gain to image signals generated by the light sensors of the imaging device, and in that the light pulses are light pulses of high power in order to reduce image noise in the images captured by the imaging device. characterized in that the imaging device is configured to convert light to electrical signals without using any electrical amplifier to provide gain to image signals generated by the light sensors of the imaging device, and in that the light pulses are light pulses of high power in order to reduce image noise in the images captured by the imaging device.
A peptide analogue comprising a peptide and one or more branched amino acid probes, wherein said branched amino acid probe comprises a first amino-alkyl amino acid residue, said first amino-alkyl amino acid residue optionally being covalently linked to a second amino-alkyl amino acid residue, or to a second and a third amino-alkyl amino acid residue, to form a linear chain of 2 or 3 amino-alkyl amino acid residues, wherein the side chain of one or more of said first, second and/or third amino-alkyl amino acid residues are each modified by attaching to the side chain amino group a molecule independently selected from the group consisting of AAA q -AAA; (aa 3) p -AAA q; AAA q -(aa 3) p; [(aa 3)-AAA] p and [AAA-(aa 3)] p; wherein q is a number selected from 0, 1, 2 and 3; p is a number selected from 1, 2 and 3; AAA is an amino-alkyl amino acid residue; and (aa 3) is an amino acid residue independently selected from Arg, His, Gly and Ala, wherein said amino-alkyl amino acid residues are optionally acetylated, wherein said first amino-alkyl amino acid residue is covalently linked to the N-terminus of said peptide, covalently linked to the C-terminus of said peptide, and/or attached to the side chain amino group of an amino-alkyl amino acid residue within said peptide, with the proviso that said branched amino acid probe consists of 2 to 9 amino acid residues; wherein said peptide is not an α-MSH and/or a γ-MSH peptide having a branched amino acid probe covalently linked to the N-terminal amino acid of said α-MSH and/or γ-MSH peptide.
A hydrogen production system comprising: a plurality of cell stacks provided within a reaction containment, the cell stacks configured to generate hydrogen by high temperature steam electrolysis by supplying steam to the plurality of cell stacks; a first flow path configured to guide the steam to each of the cell stacks; a second flow path configured to cause a gas containing air as a main component to flow into the reaction containment; and an orifice plate provided at an inlet of the steam in each of the cell stacks, the orifice plate having a hole for regulating a flow rate of the steam caused to flow into each of the cell stacks to be uniform. a plurality of cell stacks provided within a reaction containment, the cell stacks configured to generate hydrogen by high temperature steam electrolysis by supplying steam to the plurality of cell stacks; a first flow path configured to guide the steam to each of the cell stacks; a second flow path configured to cause a gas containing air as a main component to flow into the reaction containment; and an orifice plate provided at an inlet of the steam in each of the cell stacks, the orifice plate having a hole for regulating a flow rate of the steam caused to flow into each of the cell stacks to be uniform.
Hose line (1, 21) with - a hose sheath (4, M) which extends axially between a first hose end (2, 22) and a second hose end (3, 23) and has a sheath outer face (5, N) and a sheath inner face (6, I), - at least one axial passage (7, 24) enclosed by the sheath inner face (6, I) and extending axially between the hose ends (2, 22; 3, 23), - at least one radial passage (8, 25) which extends substantially radially through the hose sheath (4, M) and fluidically connects the at least one axial passage (7, 24) to the sheath outer face (5, N), and - at least one closure (9, 30) which is arranged between the radial passage (8, 25) and the second hose end (3, 23) and closes the at least one axial passage (7, 24) in a fluid-tight manner in the direction of the second hose end (3, 23), characterized in that - the at least one radial passage (8, 25) is formed by a hose sheath portion (11, 31) which is bent substantially radially inwards and which is partially separated from the rest of the hose sheath (4, M) along a partition line, wherein - the at least one closure (9, 30) is formed by means of the hose sheath portion (11, 31) being placed onto the sheath inner face (6, I) and being connected thereto in a fluid-tight manner. - a hose sheath (4, M) which extends axially between a first hose end (2, 22) and a second hose end (3, 23) and has a sheath outer face (5, N) and a sheath inner face (6, I), - at least one axial passage (7, 24) enclosed by the sheath inner face (6, I) and extending axially between the hose ends (2, 22; 3, 23), - at least one radial passage (8, 25) which extends substantially radially through the hose sheath (4, M) and fluidically connects the at least one axial passage (7, 24) to the sheath outer face (5, N), and - at least one closure (9, 30) which is arranged between the radial passage (8, 25) and the second hose end (3, 23) and closes the at least one axial passage (7, 24) in a fluid-tight manner in the direction of the second hose end (3, 23), characterized in that - the at least one radial passage (8, 25) is formed by a hose sheath portion (11, 31) which is bent substantially radially inwards and which is partially separated from the rest of the hose sheath (4, M) along a partition line, wherein - the at least one closure (9, 30) is formed by means of the hose sheath portion (11, 31) being placed onto the sheath inner face (6, I) and being connected thereto in a fluid-tight manner.
A double-coated tape (100, 200, 300, 400) comprising, in the following order: a first pressure-sensitive adhesive layer (120, 220, 320); a first plastic skin layer (130, 230, 430); an elastic base layer (140, 240, 440) having an average thickness of no more than 130 micrometers; a second plastic skin layer (132, 232, 432); and a second pressure-sensitive adhesive layer (122, 222, 322), wherein the first pressure-sensitive adhesive layer (120, 220, 320) and the second pressure-sensitive adhesive layer (122, 222, 322) are outermost layers on either side of the double-coated tape, wherein the double-coated tape has an overall thickness ranging from 50 micrometers to 400 micrometers. a first pressure-sensitive adhesive layer (120, 220, 320); a first plastic skin layer (130, 230, 430); an elastic base layer (140, 240, 440) having an average thickness of no more than 130 micrometers; a second plastic skin layer (132, 232, 432); and a second pressure-sensitive adhesive layer (122, 222, 322), wherein the first pressure-sensitive adhesive layer (120, 220, 320) and the second pressure-sensitive adhesive layer (122, 222, 322) are outermost layers on either side of the double-coated tape, wherein the double-coated tape has an overall thickness ranging from 50 micrometers to 400 micrometers.
A composition comprising human T-cells expressing a second chimeric antigen receptor for use in a method of treating a disease or condition that is a B cell malignancy in a human subject, the method comprising administering the composition to a human subject who has previously been treated with cells expressing a first chimeric antigen receptor, wherein: the first CAR specifically binds to an antigen associated with the disease or condition in the subject, wherein the antigen is selected from among CD19, CD20 and CD22; the disease or condition has relapsed or persists in the subject following administration of cells expressing the first CAR; and the second CAR, which is distinct from the first CAR, specifically binds to another antigen associated with the disease or condition that is selected from among CD19, CD22 and CD20 that is distinct from the antigen bound by the first CAR. the first CAR specifically binds to an antigen associated with the disease or condition in the subject, wherein the antigen is selected from among CD19, CD20 and CD22; the disease or condition has relapsed or persists in the subject following administration of cells expressing the first CAR; and the second CAR, which is distinct from the first CAR, specifically binds to another antigen associated with the disease or condition that is selected from among CD19, CD22 and CD20 that is distinct from the antigen bound by the first CAR.